Scarica l'app Stockscreener
0.8469
0.46%
-0.0039
Pre-mercato:
.85
0.0031
+0.37%
Precedente Chiudi:
$0.8508
Aprire:
$0.8393
Volume 24 ore:
703.90K
Relative Volume:
0.40
Capitalizzazione di mercato:
$83.04M
Reddito:
$190.00K
Utile/perdita netta:
$-74.12M
Rapporto P/E:
-1.0637
EPS:
-0.7962
Flusso di cassa netto:
$-62.06M
1 W Prestazione:
+6.84%
1M Prestazione:
-14.45%
6M Prestazione:
+19.30%
1 anno Prestazione:
-71.39%
Intervallo 1D:
$0.812
$0.87
Intervallo di 1 settimana:
$0.72
$0.87
Portata 52W:
$0.64
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
Nome
Atyr Pharma Inc
Settore
Industria
Telefono
(858) 731-8389
Indirizzo
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.8469 | 83.04M | 190.00K | -74.12M | -62.06M | -0.7962 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-09-15 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-09-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-18 | Iniziato | Leerink Partners | Outperform |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-04 | Iniziato | Wells Fargo | Overweight |
| 2024-09-05 | Iniziato | Jefferies | Buy |
| 2023-07-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-10-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-09-21 | Iniziato | Piper Sandler | Overweight |
| 2021-05-10 | Iniziato | Laidlaw | Buy |
| 2020-08-17 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Iniziato | ROTH Capital | Buy |
| 2020-03-02 | Iniziato | Oppenheimer | Outperform |
| 2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2017-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2016-12-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2015-12-16 | Iniziato | Citigroup | Neutral |
| 2015-06-01 | Iniziato | Citigroup | Buy |
| 2015-06-01 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Atyr Pharma Inc Borsa (ATYR) Ultime notizie
Market Wrap: Is aTyr Pharma Inc in a bullish channelM&A Rumor & Comprehensive Market Scan Insights - baoquankhu1.vn
ATYR Technical Analysis & Stock Price Forecast - Intellectia AI
Downgrade Watch: Is aTyr Pharma Inc backed by strong institutional buying2026 Stock Rankings & Daily Growth Stock Investment Tips - baoquankhu1.vn
Performance Recap: Is aTyr Pharma Inc in a bullish channel2026 Momentum Check & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
aTyr Pharma (NASDAQ: ATYR) seeks approval to double share authorization - Stock Titan
[ARS] aTYR PHARMA INC SEC Filing - stocktitan.net
Vanguard disaggregates holdings; reports 0 shares in aTyr Pharma (ATYR) - Stock Titan
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Recommendation of "Hold" by Analysts - marketbeat.com
ATyr Pharma Announces Scheduling of FDA Type - Moomoo
HC Wainwright & Co. Downgrades aTyr Pharma (ATYR) - MSN
aTyr Pharma Inc Stock (ISIN: US53227K1025) Faces Uncertainty Amid Delisting Risk and Pipeline Focus - AD HOC NEWS
aTyr Pharma (NASDAQ:ATYR) Upgraded at Wall Street Zen - MarketBeat
Does aTyr Pharma Inc stock benefit from AI growth2026 Analyst Calls & Precise Entry and Exit Recommendations - baoquankhu1.vn
aTyr Pharma (NASDAQ: ATYR) asks shareholders to double authorized shares to 340M - Stock Titan
aTyr Pharma Spotlights Efzofitimod Phase 3 Learnings, Eyes Mid-April FDA Type C Meeting - MarketBeat
Investigation announced for Long-Term Investors in shares - openPR.com
aTyr Pharma (ATYR) Receives a Buy from Piper Sandler - The Globe and Mail
Q1 Earnings Estimate for aTyr Pharma Issued By HC Wainwright - MarketBeat
Atyr Pharma Faces Nasdaq Delisting Risk After Minimum Bid Price Violation - The Globe and Mail
Jefferies Maintains Buy on ATYR aTyr Pharma, Inc. March 2026 - Meyka
Jefferies reiterates aTyr Pharma stock rating on regulatory outlook By Investing.com - Investing.com Canada
Jefferies reiterates aTyr Pharma stock rating on regulatory outlook - Investing.com UK
aTyr Pharma 2025 Financials: Q4 Loss Narrows, Annual Revenue SteadyNews and Statistics - IndexBox
Atyr Pharma: Fourth Quarter Earnings Overview - Bitget
aTyr Pharma (NASDAQ:ATYR) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
aTyr (ATYR) Achieves Milestone with Phase 3 Study Results - GuruFocus
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update - The Manila Times
Atyr Pharma: Q4 Earnings Snapshot - marketscreener.com
ATyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update - marketscreener.com
aTyr Pharma (ATYR) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
ATYR Financials: Income Statement, Balance Sheet & Cash Flow | Atyr Pharma Inc - Stock Titan
ATYR PE Ratio & Valuation, Is ATYR Overvalued - Intellectia AI
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Recommendation of "Hold" by Analysts - marketbeat.com
aTyr Pharma Faces Pivotal Regulatory and Financial Milestones - AD HOC NEWS
aTyr Pharma (ATYR) Stock Analysis: Exploring a Potential 327% Upside in the Biotech Sector - DirectorsTalk Interviews
aTyr Pharma Q4 2025 Earnings Call Transcript - MarketBeat
aTyr Pharma (NASDAQ:ATYR) Trading Down 2.1%Should You Sell? - MarketBeat
ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Biotech aTyr gives new employees 12,200 stock options at $0.98 - stocktitan.net
aTyr Pharma, Inc. (ATYR) Stock Analysis: Unveiling a Potential 338% Upside in the Biotechnology Arena - DirectorsTalk Interviews
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference - Bitget
aTyr Pharma Insiders Added US$926.8k Of Stock To Their Holdings - simplywall.st
Sentiment Recap: Does aTyr Pharma Inc stock benefit from AI growth2025 Volatility Report & AI Forecast Swing Trade Picks - baoquankhu1.vn
Levels Update: Will CompoSecure Inc Equity Warrant stock go up in YEARVolume Spike & Low Volatility Stock Recommendations - baoquankhu1.vn
The Truth About aTyr Pharma Inc (LIFE): Tiny Stock, Huge Bets – But Is It Worth the Hype? - AD HOC NEWS
Is aTyr Pharma Inc. stock cheap compared to fundamentalsQuarterly Risk Review & Verified Swing Trading Watchlist - mfd.ru
Is aTyr Pharma Inc. backed by strong institutional buyingWeekly Trend Report & Smart Investment Allocation Tips - mfd.ru
Why hedge funds are buying aTyr Pharma Inc. stock2025 EndofYear Setup & Risk Managed Investment Entry Signals - mfd.ru
Why analysts upgrade aTyr Pharma Inc. stockJuly 2025 Fed Impact & Capital Protection Trade Alerts - mfd.ru
Facioscapulohumeral Muscular Dystrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com
Atyr Pharma Inc Azioni (ATYR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):